Ligand Pharmaceuticals Incorporated
NASDAQ:LGNDBiotechnology
+$2.89 today
- Market cap
- $5.98B
- Beta
- 1.04
- P/E (TTM)
- 34.4
- EPS (TTM)
- $7.72
Volume 0.38M
Average 0.22M
LGND Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Ligand Pharmaceuticals IncorporatedNASDAQ: LGND
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income growth accelerates
Q2 FY2026 net income of $48.51M rose 900.8% year over year, ahead of the +360.0% change in trailing-twelve-month net income.
Context
- Net income amounted to 46.4% of revenue in FY2025, up 44.0 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 8 analysts of $193.74M (+55.7%) for the fiscal year ending Dec 2026, a slowdown from the +3186.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $48.51M+463.5% QoQ
- Last fiscal yearDec 2025
- $124.45M+3186.6% YoY
- LTMJun 2026
- $197.22M+360.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +900.8% | -60.4% | -961.1 pp |
| 1 year | +3186.6% | +55.7% | -3131.0 pp |
| 3-year CAGR | — | +31.8% | — |
| 5-year CAGR | +26.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 124.45M USD
- Year-over-year change
- +3186.6%
- 4-year CAGR
- +21.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 124.45M | +3186.6% |
| FY2024 | 2024-12-31 | (4.03M) | -107.7% |
| FY2023 | 2023-12-31 | 52.15M | +256.3% |
| FY2022 | 2022-12-31 | (33.36M) | -158.4% |
| FY2021 | 2021-12-31 | 57.14M | — |
Net Income vs competitors
How LGND compares with its peers on the latest reported figures
- LGND's LTM Jun 2026 net income of $197.22M is the smallest of the 10 companies compared; the peer median is $1.61B.
- Its year-over-year change of +360.0% is the 3rd highest of 9, against a peer median of +74.7%.
- Net income amounts to 67.9% of revenue for LGND, versus a peer median of 22.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $9.27B | +83.1% | +3.6% | 18.9% | |
| LTM Jun 2026 | $8.74B | +32.1% | +5.6% | 22.9% | |
| LTM Jun 2026 | $6.32B | +66.4% | -29.1% | 9.8% | |
| LTM Jun 2026 | $4.37B | -59.4% | -37.2% | 6.9% | |
| LTM Jun 2026 | $1.61B | +85.1% | +55.7% | 27.7% | |
| LTM Jun 2026 | $861.1M | — | -48.4% | 20.8% | |
| LTM Jul 2026 | $860.62M | +42.9% | +62.5% | 35.3% | |
| LTM Mar 2026 | $364.23M | +879.7% | — | 121.5% | |
| LTM Jun 2026 | $268.25M | +651.2% | — | 28.5% | |
| LTM Jun 2026 | $197.22M | +360.0% | — | 67.9% | |
| Peer median (excluding LGND) | $1.61B | +74.7% | +3.6% | 22.9% | |
Competitors are the stored peer set for LGND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 57.14M | (33.36M) | 52.15M | (4.03M) | 124.45M |
| Depreciation & Amortization | 50.95M | 43.39M | 36.52M | 35.24M | 33.78M |
| Deferred Income Tax | (8.62M) | 20.72M | 11.7M | (15.8M) | 22.68M |
| Stock-Based Compensation | 38.78M | 60.29M | 25.74M | 41.09M | 0 |
| Change in Working Capital | (52.16M) | 65.68M | (34.4M) | 19.36M | (12.67M) |
| Accounts Receivables | (28.62M) | 55.32M | (2.6M) | (6.46M) | (21.74M) |
| Inventory | (427K) | 12.06M | (10.87M) | 9.62M | 4.99M |
| Accounts Payables | (1.17M) | (3.34M) | (4.7M) | 0 | 5.88M |
| Other Working Capital | (21.96M) | 1.64M | (16.23M) | 16.2M | (1.8M) |
| Other Non-Cash Items | (7.29M) | (18.87M) | (42.14M) | 21.2M | (118.89M) |
| Operating Cash Flow | 78.8M | 137.85M | 49.58M | 97.05M | 49.36M |
| Capital Expenditures | (8.76M) | (17.92M) | (53.85M) | (19.64M) | (452K) |
| Acquisitions (Net) | 494K | (750K) | (25.65M) | (172.19M) | (8.09M) |
| Purchases of Investments | (181.33M) | (51.23M) | (126.76M) | (226.38M) | (730.86M) |
| Sales of Investments | 221.34M | 234.39M | 194.17M | 269.62M | 377.28M |
| Other Investing Activities | (1.22M) | (868K) | (49.91M) | (12.89M) | (4.34M) |
| Investing Cash Flow | 30.52M | 163.62M | (11.68M) | (143.66M) | (377.32M) |
| Debt Repayment | (146.01M) | (260.8M) | (76.9M) | (25K) | 338.11M |
| Common Stock Issued | 33.76M | 3.23M | 22.45M | 37.14M | 114.89M |
| Common Stock Repurchased | (18.45M) | 0 | 0 | 0 | (15M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (7.07M) | (18.42M) | (5.5M) | 60.03M | (9.77M) |
| Financing Cash Flow | (137.76M) | (275.99M) | (59.95M) | 97.14M | 428.22M |
| Effect of Forex Changes | 0 | 0 | 0 | (1.17M) | 2.36M |
| Net Change in Cash | (28.44M) | 25.48M | (22.05M) | 49.35M | 102.62M |
| Free Cash Flow | 70.04M | 119.93M | (4.27M) | 77.41M | 48.91M |
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
Intrinsic Alpha fair value
Locked
Current Price
$298.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.